News at the Oxford-GSK Institute of Molecular and Computational Medicine
Toxic Cargoes Contributing to Dementia are Contained Within Extracellular Vesicles
23 January 2025
New research led by Dr Steph Fowler (UCL and now Oxford IMCM), Professor Karen Duff (UKDRI, UCL), with Dr Benjamin Ryskeldi-Falcon and Dr Tiana Behr (MRC LMB), have shed light on a potential pathway for the spread of harmful tau protein in Alzheimer's disease. Their findings, published in Nature Neuroscience, focus on structures called extracellular vesicles and their role in transporting toxic tau fragments.
Third Oxford-GSK Annual Meeting
23 January 2025
September 26th 2024 saw a record number of Oxford and GSK colleagues come together at St Anne's college. Researchers and scientists took to the platform to update the audience on the significant progress the IMCM research projects and other Oxford-GSK collaborations had made during the year.
Three New Fellows Join the IMCM
14 November 2024
Each of the Fellows is leading an independent research programme that complements the aims and activities of the Oxford-GSK IMCM to address the problems of patient stratification, heterogeneity and disease taxonomy in neurodegenerative diseases, which have become significant barriers to drug development.
Our Team
31 August 2023
Talented scientists from across the world have joined our team. We have been honoured by the quality of applicants keen to join us as the institute. By the end of Q3 2023 we will have filled all of our posts. Not only are we bringing in new talent, we are also collaborating with with highly experienced colleagues from across GSK and Oxford University.
Progress in 2023 - putting data to work for patients
31 August 2023
Everything we do is to enable the delivery of targeted successful treatments to patients. Initially our focus is on diseases driven by neuro-immunological mechanisms including Alzheimer’s, Parkinson’s, and Amyotrophic Lateral Sclerosis (ALS).